var data={"title":"Diazepam: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Diazepam: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6013?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=diazepam-drug-information\" class=\"drug drug_general\">see &quot;Diazepam: Drug information&quot;</a> and <a href=\"topic.htm?path=diazepam-patient-drug-information\" class=\"drug drug_patient\">see &quot;Diazepam: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50711533\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">FDA Extends Expiration Dates for Certain Meridian Autoinjectors: Updated</span>\n      <span class=\"collapsible-date\">July 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;margin-top:2em;\">The FDA is alerting health care providers and emergency responders that certain lots of <i>AtroPen</i> (atropine), <i>CANA</i> (diazepam), morphine sulfate, and pralidoxime chloride autoinjectors manufactured by Meridian Medical Technologies can be used beyond the labeled expiration date, which should help mitigate potential shortages of these drugs. To ensure patient safety, products should be stored under the manufacturer&rsquo;s labeled storage conditions.</p>\n        <p style=\"text-indent:0em;margin-top:2em;\">Additional information may be found at <a target=\"_blank\" href=\"http://www.fda.gov/Drugs/DrugSafety/ucm376367.htm&amp;token=SHauxSdf9qNc6lLK16E8IDV3KxAgJ9eAUWFzIj8OhB+DS1QnG3nll2ktzEV1bFFqNvp/S6dk6auUFKQXeUZdHA==&amp;TOPIC_ID=13223\" target=\"_blank\">http://www.fda.gov/Drugs/DrugSafety/ucm376367.htm</a>.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49351801\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risks from concomitant use with opioids</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F159030\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Diastat AcuDial;</li>\n      <li>Diastat Pediatric;</li>\n      <li>DiazePAM Intensol;</li>\n      <li>Valium</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F159031\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Diazepam;</li>\n      <li>Bio-Diazepam;</li>\n      <li>Diastat;</li>\n      <li>Diazemuls;</li>\n      <li>Diazepam Auto Injector;</li>\n      <li>Diazepam Injection SDZ;</li>\n      <li>Diazepam Injection USP;</li>\n      <li>Novo-Dipam;</li>\n      <li>PMS-Diazepam;</li>\n      <li>Valium</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052159\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antianxiety Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Anticonvulsant, Benzodiazepine</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Benzodiazepine</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Hypnotic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Sedative</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442291\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">\n      <b>Status epilepticus:</b> IV: (Not recommended as first-line agent; use only after multiple agents have failed; injection contains benzoic acid, sodium benzoate, and benzyl alcohol): 0.1 to 0.3 mg/kg/dose given over 3 to 5 minutes, every 15 to 30 minutes, to a maximum total dose of 2 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052150\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=diazepam-drug-information\" class=\"drug drug_general\">see &quot;Diazepam: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Seizures, acute: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Rectal gel formulation:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Infants and Children 6 months to 2 years: Rectal: Dose not established </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Children 2 to 5 years: Rectal: 0.5 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Children 6 to 11 years: Rectal: 0.3 mg/kg </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Children &ge;12 years and Adolescents: Rectal: 0.2 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">\n      <b>Note:</b> Round dose to the nearest 2.5 mg increment, not exceeding a 20 mg/dose; dose may be repeated in 4 to 12 hours if needed; do not use more than 5 times per month or more than once every 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Rectal: Undiluted 5 mg/mL parenteral formulation (filter if using ampul): Infants, Children, and Adolescents: 0.5 mg/kg/dose then 0.25 mg/kg/dose in 10 minutes if needed. Maximum dose: 20 mg/dose (Hegenbarth 2008; Kliegman 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Status epilepticus:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Weight-directed: Infants &gt;30 days, Children, and Adolescents: IV: 0.1 to 0.3 mg/kg/dose given over 3 to 5 minutes, every 5 to 10 minutes; maximum dose: 10 mg/dose (Brophy 2012; Hegenbarth 2008) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Fixed dosing: Manufacturer's labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Infants &gt;30 days and Children &lt;5 years: IV: 0.2 to 0.5 mg slow IV every 2 to 5 minutes up to a maximum total dose of 5 mg; repeat in 2 to 4 hours if needed </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Children &ge;5 years and Adolescents: IV: 1 mg slow IV every 2 to 5 minutes up to a maximum of 10 mg; repeat in 2 to 4 hours if needed </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Febrile seizure, prophylaxis:</b> Limited data available: Children: Oral: 1 mg/kg/day divided every 8 hours; initiate therapy at first sign of fever and continue for 24 hours after fever resolves (Rosman 1993; Steering Committee 2008) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Spasticity/muscle spasms: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>General dosing:</i> <b>Note:</b> Initiate therapy with lowest dose; dose should be individualized and titrated to effect and tolerability:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Manufacturer's labeling: Infants &ge;6 months, Children, and Adolescents: Oral: Initial: 1 to 2.5 mg 3 to 4 times daily; increase gradually as needed and tolerated</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Alternate dosing (Kliegman 2016):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">Infants &ge;6 months and Children &lt;12 years: 0.12 to 0.8 mg/kg/day in divided doses every 6 to 8 hours; maximum dose: 10 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">Children &ge;12 years and Adolescents: 2 to 10 mg 2 to 4 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Cerebral palsy-associated spasticity:</i> Limited data available. <b>Note:</b> Dose should be individualized and titrated to effect and tolerability: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Weight-based dosing: Children: Oral: 0.01 to 0.3 mg/kg/day divided 2 <b>or</b> 4 times daily (Kliegman 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Low-dose fixed dosing (Mathew 2005): Children &lt;12 years: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">&lt;8.5 kg: 0.5 to 1 mg at bedtime </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">8.5 to 15 kg: 1 to 2 mg at bedtime</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Fixed dosing: Children &ge;5 years and Adolescents: Oral: Initial: 1.25 mg 3 times daily; may titrate to 5 mg 4 times daily (Engle 1966)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Tetanus-associated spasm: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Manufacturer's labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Infants &gt;30 days and children &lt;5 years: IV, IM: 1 to 2 mg every 3 to 4 hours as needed </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Children &ge;5 years and Adolescents: IV, IM: 5 to 10 mg every 3 to 4 hours as needed </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Alternate dosing (WHO 2010):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Infants and Children: IV: Initial: 0.1 to 0.2 mg/kg/dose every 2 to 6 hours; titrate as needed</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Adolescents: IV: Initial: 5 mg every 2 to 6 hours, titrate as needed. Large doses may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Muscle spasm/spasticity associated with chronic/terminal illness (eg, palliative care settings):</i> Limited data available: Infants, Children, and Adolescents: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Oral:  0.12 to 0.8 mg/kg/day divided every 6 to 12 hours; maximum dose: 10 mg/dose (Wustoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">IM, IV: 0.05 to 0.2 mg/kg/dose every 6 to 12 hours; maximum total dose: 0.6 mg/kg cumulative in 8 hours (Wustoff 2007); <b>Note:</b> In palliative situations, the usual initial dose for children &lt;5 years is 5 mg/dose and in children &ge;5 years and adolescents is 10 mg/dose (Kliegman 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Sedation, anxiolysis, and amnesia prior to procedure:</b> Limited data available: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\"> Infants &ge;6 months: 0.2 to 0.3 mg/kg 45 to 60 minutes prior to procedure. Maximum dose: 10 mg/dose (Zeltzer 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Children: 0.2 to 0.5 mg/kg 45 to 60 minutes prior to procedure; maximum dose: 10 mg/dose (Everitt 2002; Fell 1985; Tyagi 2012; Zeltzer 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Adolescents: 0.2 to 0.3 mg/kg 45 to 60 minutes prior to procedure. Maximum dose: 10 mg/dose (Zeltzer 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IV: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Infants and Children: Initial: 0.05 to 0.1 mg/kg over 3 to 5 minutes, titrate slowly to effect (maximum total dose: 0.25 mg/kg) (Krauss 2006) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Adolescents: IV: 5 mg; may repeat with 2.5 mg if needed (Zeltzer 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> Oral absorption is more reliable than IM.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute ethanol withdrawal:</b> Oral: 10 mg 3 to 4 times during first 24 hours, then decrease to 5 mg 3 to 4 times daily as needed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anxiety (symptoms/disorders):</b> Oral, IM, IV: 2 to 10 mg 2 to 4 times daily if needed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Muscle spasm:</b> IV, IM: Initial: 5 to 10 mg; then 5 to 10 mg in 3 to 4 hours, if necessary. Larger doses may be required if associated with tetanus.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rapid tranquilization of agitated patient</b> (administer every 30 to 60 minutes): Oral: 5 to 10 mg; average total dose for tranquilization: 20 to 60 mg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Seizures:</b> Rectal gel (Diastat): 0.2 mg/kg (maximum dose: 20 mg); may be repeated in 4 to 12 hours if needed; do not use for more than 5 episodes per month or more than one episode every 5 days. <b>Note:</b> Dosage should be rounded upward to the next available dose (2.5, 5, 7.5, 10, 12.5, 15, 17.5, or 20 mg/dose).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Status epilepticus</b>: IV: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: 5 to 10 mg given at a rate of &le;5 mg/minute; may repeat every 10 to 15 minutes (maximum total dose: 30 mg) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neurocritical Care Society recommendations: 0.15 mg/kg (maximum dose: 10 mg) given at a rate of &le;5 mg/minute; may repeat in 5 minutes (Brophy 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skeletal muscle relaxant (adjunct therapy):</b> Oral: 2 to 10 mg 3 to 4 times daily </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: Not dialyzable (0% to 5%); supplemental dose is not necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; use with caution. The oral tablets are contraindicated in severe hepatic impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F159001\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Concentrate, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">DiazePAM Intensol: 5 mg/mL (30 mL) [contains alcohol, usp; unflavored flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg/mL (30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gel, Rectal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Diastat AcuDial: 10 mg (1 ea); 20 mg (1 ea) [contains alcohol, usp, benzoic acid, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Diastat Pediatric: 2.5 mg (1 ea) [contains benzoic acid, benzyl alcohol, propylene glycol, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2.5 mg (1 ea); 10 mg (1 ea); 20 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg/mL (2 mL, 10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg/mL (5 mL [DSC], 500 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Auto-injector, Intramuscular: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/2 mL (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Valium: 2 mg, 5 mg, 10 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2 mg, 5 mg, 10 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158984\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F159082\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;display:inline\">C-IV</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49627710\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Valium: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/013263s094lbl.pdf#page=14&amp;token=ZcAVMNOY2zROI8K74jTu0nWEdsmNnMT9m/Gn/7gmhsPaOGqlT7sHW+8wFX9pI0cQxIQ84D08lsW5Yc83X5RqgPlAcvj1N0VUlclrUM/Ofh5hQ1eRnWzmOt3qHxDSuz6p&amp;TOPIC_ID=13223\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/013263s094lbl.pdf#page=14</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052165\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Administer with food or water. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral concentrate solution (5 mg/mL): Dilute or mix product before use. Measure dose only with calibrated dropper provided.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Parenteral: IV: Administer undiluted (5 mg/mL) direct IV; do not mix with other solutions or medications. Rapid injection may cause respiratory depression or hypotension; infants and children: Do not exceed 1 to 2 mg/minute IV push; adults: 5 mg/minute. Continuous infusion is not recommended because of precipitation in IV fluids and absorption of drug into infusion bags and tubing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. If extravasation occurs, stop IV administration immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do NOT flush the line); remove needle/cannula; elevate extremity. Apply dry cold compresses (Hurst 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rectal: Diastat AcuDial: Prior to administration, confirm that the prescribed dose is visible and correct and that the green &quot;ready&quot; band is visible. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Diastat AcuDial and Diastat: Place patient on side (facing person responsible for monitoring), with top leg bent forward. Insert rectal tip (lubricated) gently into rectum until rim fits snug against rectal opening; push plunger gently over 3 seconds. After additional 3 seconds, remove syringe; hold buttocks together while slowly counting to 3 to prevent leakage; keep patient on side, facing towards you and continue to observe patient; discard any unused medication, syringe, and all used materials safely away from children; do not reuse; see Administration and Disposal Instructions that come with product.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F159023\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from light. Do not refrigerate autoinjector.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral solution: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light. Discard opened bottle of concentrated oral solution after 90 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rectal gel: Store at 25&deg;C (77&deg;F); excursion permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052164\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Management of general anxiety disorders, ethanol withdrawal symptoms, relief of skeletal muscle spasms, and muscle spasticity; adjunct in the treatment of convulsive disorders (FDA approved in ages &ge;6 months and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Management of muscle spasms associated with tetanus (FDA approved in ages &gt;30 days and adults); adjunct treatment of status epilepticus and severe recurrent convulsive disorders (FDA approved in ages &gt;30 days and adults); management of general anxiety disorders, ethanol withdrawal symptoms, relief of skeletal muscle spasms, muscle spasticity, and tetany (FDA approved in adults); to provide preoperative or preprocedural sedation and amnesia (FDA approved in adults) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rectal gel: Management of intermittent bouts of increased seizure activity in refractory epilepsy patients on stable AED therapy (FDA approved in ages &ge;2 years and adults) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F159090\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">DiazePAM may be confused with diazoxide, dilTIAZem, Ditropan, LORazepam</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Valium may be confused with Valcyte</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Diazepam is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older due to an increased risk of impaired cognition, delirium, falls, fractures, and motor vehicle accidents with benzodiazepine use. Older adults also have slower metabolism of long-acting benzodiazepines (eg, diazepam). However, diazepam<i> may be appropriate </i>in older adults when used for seizure disorders, rapid eye movement disorders, benzodiazepine or ethanol withdrawal, severe generalized anxiety disorder, or periprocedural anesthesia (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F159087\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse reactions may vary by route of administration. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Cardiovascular: Hypotension, localized phlebitis, vasodilatation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Amnesia, ataxia, confusion, depression, drowsiness, dysarthria, fatigue, headache, slurred speech, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Change in libido</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Altered salivation (dry mouth or hypersalivation), constipation, diarrhea, nausea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Urinary incontinence, urinary retention</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Jaundice </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Blurred vision, diplopia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Apnea, asthma, bradypnea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Paradoxical reaction (eg, aggressiveness, agitation, anxiety, delusions, hallucinations, inappropriate behavior, increased muscle spasms, insomnia, irritability, psychoses, rage, restlessness, sleep disturbances, stimulation)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F159009\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to diazepam or any component of the formulation; acute narrow-angle glaucoma; untreated open-angle glaucoma; infants &lt;6 months of age (oral); myasthenia gravis, severe respiratory impairment, severe hepatic impairment, sleep apnea syndrome (oral tablet).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for benzodiazepines is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158988\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anterograde amnesia: Benzodiazepines have been associated with anterograde amnesia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Paradoxical reactions: Paradoxical reactions, including hyperactive or aggressive behavior, hallucinations, and psychoses, have been reported with benzodiazepines, particularly in pediatric or elderly patients. Discontinue if such reactions occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Convulsive disorders: When used as an adjunct in treating convulsive disorders, an increase in frequency/severity of tonic-clonic seizures may occur and require dose adjustment of anticonvulsant. Abrupt withdrawal may result in a temporary increase in the frequency and/or severity of seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Depression: Use caution in patients with depression or anxiety associated with depression, particularly if suicidal risk may be present.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug abuse: Use with extreme caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance and psychological and physical dependence may occur with prolonged use (generally &gt;10 days).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Glaucoma: May be used in patients with open-angle glaucoma who are receiving appropriate therapy; contraindicated in acute narrow-angle glaucoma and untreated open-angle glaucoma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment. Oral tablet is contraindicated in patients with severe hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Impaired gag reflex: Use benzodiazepines with caution in patients with an impaired gag reflex.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disease: Use with caution in patients with respiratory disease; a lower dose is recommended for chronic respiratory insufficiency. Oral tablet is contraindicated in patients with severe respiratory impairment or sleep apnea syndrome.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Concomitant use with opioids:<b> [US Boxed Warning]: </b><b>Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death; reserve concomitant prescribing of these drugs for use in patients for whom </b><b>alternative treatment options are inadequate, and limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Debilitated/Elderly patients: Use with caution; active metabolites with extended half-lives may lead to delayed accumulation and adverse effects; limit dose to smallest effective amount and increase gradually and as tolerated to avoid adverse reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fall risk: Use with extreme caution in patients who are at risk of falls; benzodiazepines have been associated with falls and traumatic injury.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Obese patients: Use benzodiazepines with caution in obese patients; may have prolonged action when discontinued.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychotic patients: Use of diazepam is not recommended in place of appropriate therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol and/or sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&quot;gasping syndrome&quot;) in neonates; the &quot;gasping syndrome&quot; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggest that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol and/or benzyl alcohol derivative with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Parenteral: Vesicant; ensure proper needle or catheter placement prior to and during administration; avoid extravasation. Acute hypotension, muscle weakness, apnea, and/or cardiac arrest have occurred with parenteral administration. Acute effects may be more prevalent in patients receiving concurrent barbiturates, opioids, or ethanol. Appropriate resuscitative equipment and qualified personnel should be available during administration and monitoring. Avoid use of the injection in patients in shock, coma, or in acute ethanol intoxication with depression of vital signs. Intra-arterial injection should be avoided. Tonic status epilepticus has been precipitated in patients treated with diazepam IV for absence status or absence variant status.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP [&quot;Inactive&quot; 1997]; Wilson 2000; Wilson 2005; Zar 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Rectal gel: Administration of rectal gel should only be performed by individuals trained to recognize characteristic seizure activity for which the product is indicated, and capable of monitoring response to determine need for additional medical intervention. Not recommended for chronic, daily use. Use with caution in patients with neurologic damage.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Does not have analgesic, antidepressant, or antipsychotic properties.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tolerance: Diazepam is a long half-life benzodiazepine. Duration of action after a single dose is determined by redistribution rather than metabolism. Tolerance develops to the sedative, hypnotic, and anticonvulsant effects. It does not develop to the anxiolytic or skeletal muscle relaxing effects (Vinkers 2012). Chronic use of this agent may increase the perioperative benzodiazepine dose needed to achieve desired effect.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: Rebound or withdrawal symptoms may occur following abrupt discontinuation or large decreases in dose. Use caution when reducing dose or withdrawing therapy; decrease slowly and monitor for withdrawal symptoms. The benzodiazepine receptor antagonist flumazenil may cause withdrawal in patients receiving long-term benzodiazepine therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25855859\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Neonates and young infants have decreased metabolism of diazepam and desmethyldiazepam (active metabolite), both can accumulate with repeated use and cause increased toxicity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F159074\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP2B6 (minor), CYP2C19 (major), CYP2C9 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158993\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13223&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Ajmaline: DiazePAM may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfentanil: DiazePAM may enhance the CNS depressant effect of Alfentanil. Hypotension may also occur. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benznidazole: May enhance the adverse/toxic effect of Products Containing Propylene Glycol.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Benzodiazepines may enhance the adverse/toxic effect of CloZAPine.  Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cosyntropin: May enhance the hepatotoxic effect of DiazePAM.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C19 Inhibitors (Moderate): May decrease the metabolism of CYP2C19 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C19 Inhibitors (Strong): May decrease the metabolism of CYP2C19 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP2C19 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP2C19 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Disulfiram: May increase the serum concentration of DiazePAM.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP2C19 Substrates (High risk with Inducers). Conversely, concentrations of active metabolites may be increased for those drugs activated by CYP2C19. Management: Concurrent use of enzalutamide with CYP2C19 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP2C19 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etravirine: May decrease the serum concentration of DiazePAM. Etravirine may increase the serum concentration of DiazePAM.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosamprenavir: May increase the serum concentration of DiazePAM.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Melatonin: May enhance the sedative effect of Benzodiazepines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methadone: Benzodiazepines may enhance the CNS depressant effect of Methadone.  Management: Clinicians should generally avoid concurrent use of methadone and benzodiazepines when possible; any combined use should be undertaken with extra caution.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OLANZapine: May enhance the adverse/toxic effect of Benzodiazepines. Management: Avoid concomitant use of parenteral benzodiazepines and IM olanzapine due to risks of additive adverse events (e.g., cardiorespiratory depression). Olanzapine prescribing information provides no specific recommendations regarding oral administration.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ombitasvir, Paritaprevir, and Ritonavir: May decrease the serum concentration of DiazePAM.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir: May decrease the serum concentration of DiazePAM.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May increase the serum concentration of DiazePAM.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saquinavir: May increase the serum concentration of DiazePAM.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: Benzodiazepines may enhance the CNS depressant effect of Sodium Oxybate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teduglutide: May increase the serum concentration of Benzodiazepines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: May diminish the therapeutic effect of Benzodiazepines.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Yohimbine: May diminish the therapeutic effect of Antianxiety Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158996\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F159013\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. In humans, diazepam and its metabolites (N-desmethyldiazepam, temazepam, and oxazepam) cross the placenta. Teratogenic effects have been observed with diazepam; however, additional studies are needed. The incidence of premature birth and low birth weights may be increased following maternal use of benzodiazepines; hypoglycemia and respiratory problems in the neonate may occur following exposure late in pregnancy. Neonatal withdrawal symptoms may occur within days to weeks after birth and &quot;floppy infant syndrome&quot; (which also includes withdrawal symptoms) has been reported with some benzodiazepines (including diazepam) (Bergman 1992; Iqbal 2002; Wikner 2007). A combination of factors influences the potential teratogenicity of anticonvulsant therapy. When treating women with epilepsy, monotherapy with the lowest effective dose and avoidance of medications known to have a high incidence of teratogenic effects is recommended (Harden 2009; Wlodarczyk 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052158\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Heart rate, respiratory rate, blood pressure, mental status; with long-term therapy: Liver enzymes, CBC</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052163\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Effective therapeutic range not well established </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Proposed therapeutic: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Diazepam: 0.2 to 1.5 mcg/mL (SI: 0.7 to 5.3 micromoles/L) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">N-desmethyldiazepam (nordiazepam): 0.1 to 0.5 mcg/mL (SI: 0.35 to 1.8 micromoles/L)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158987\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Binds to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron at several sites within the central nervous system, including the limbic system, reticular formation. Enhancement of the inhibitory effect of GABA on neuronal excitability results by increased neuronal membrane permeability to chloride ions. This shift in chloride ions results in hyperpolarization (a less excitable state) and stabilization. Benzodiazepine receptors and effects appear to be linked to the GABA-A receptors. Benzodiazepines do not bind to GABA-B receptors.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F159008\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sedation: Pediatric patients: IV: 4 to 5 minutes (Krauss 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Status epilepticus: IV: 1 to 3 minutes; Rectal: 2 to 10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration of action: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sedation: Pediatric patients: 60 to 120 minutes (Krauss 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Status epilepticus: 15 to 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: Well absorbed (&gt;90%); delayed and decreased when administered with a moderate fat meal</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rectal: Well absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: 1.2 L/kg (range: 0.6 to 2 L/kg)  (Greenblatt 1989a)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: 1.1 L/kg (range: 0.6 to 1.8 L/kg (Greenblatt 1989b)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rectal: 1 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding:  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: Neonates: 84% to 86% (Milsap 1994; Morselli 1980); Adults: 98%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rectal: 95% to 98%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic; diazepam is N-demethylated by CYP3A4 and 2C19 to the active metabolite N-desmethyldiazepam, and is hydroxylated by CYP3A4 to the active metabolite temazepam.  N-desmethyldiazepam and temazepam are both further metabolized to oxazepam. Temazepam and oxazepam are largely eliminated by glucuronidation. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM: &gt;90% (Lamson 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: &gt;90%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rectal: 90%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: <b>Note:</b> Diazepam accumulates upon multiple dosing and the terminal elimination half-life is slightly prolonged.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Premature neonates (GA: 28 to 34 weeks): 54 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants: ~30 hours (Morselli 1973)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 3 to 8 years: 18 hours (Morselli 1973)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults: Parent: ~60 to 72 hours; Desmethyldiazepam: ~152 to 174 hours (Lamson 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Parent: 33 to 45 hours; Desmethyldiazepam: 87 hours (Cloyd 1998; Greenblatt 1989a)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Parent: 44 to 48 hours; Desmethyldiazepam: 100 hours (Greenblatt 1989b)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rectal: Parent: 45 to 46 hours; Desmethyldiazepam: 71 to 99 hours (Cloyd 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM: Median: 1 hour (range: 0.25 to 2 hours) (Lamson 2011) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: ~1 minute (Cloyd 1998) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: 15 minutes to 2.5 hours (1.25 hours when fasting; 2.5 hours with food) (Greenblatt 1989b)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rectal: 1.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (predominantly as glucuronide conjugates)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F159012\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Concentrate</b> (DiazePAM Intensol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/mL (30 mL): $42.99</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Concentrate</b> (DiazePAM Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/mL (30 mL): $37.38</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Diastat AcuDial Rectal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (1): $404.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (1): $404.56</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Diastat Pediatric Rectal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (1): $341.04</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (DiazePAM Rectal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (1): $306.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (1): $364.06</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (1): $364.06</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (DiazePAM Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/mL (10 mL): $43.12</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (DiazePAM Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (500 mL): $78.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Auto-injector</b> (DiazePAM Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/2 mL (2 mL): $43.07</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (DiazePAM Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (100): $14.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $22.01</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $33.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Valium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (100): $408.01</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (500): $3,157.24</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (500): $5,327.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F159015\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aliseum (IT);</li>\n      <li>Alsaval (SY);</li>\n      <li>Anlin (TW);</li>\n      <li>Ansiolin (IT);</li>\n      <li>Antenex (AU);</li>\n      <li>Anxicalm (IE);</li>\n      <li>Apaurin (CZ, HR, RU, SI, SK);</li>\n      <li>Apo-diazepam (CZ);</li>\n      <li>Apozepam (DK);</li>\n      <li>Assival (IL);</li>\n      <li>Azepam (BD);</li>\n      <li>Azepan (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Baogin (TW);</li>\n      <li>Benzopin (ZA);</li>\n      <li>Calmpose (BF, BJ, CI, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Calmvita (LK);</li>\n      <li>Cercine (JP);</li>\n      <li>Ceregulart (JP);</li>\n      <li>Compaz (BR);</li>\n      <li>Condition (JP);</li>\n      <li>D-Pam (NZ);</li>\n      <li>Dialag (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Diapam (FI, TR);</li>\n      <li>Diapine (MY, SG, TH, TW);</li>\n      <li>Diapo (MY);</li>\n      <li>Diazem (TR);</li>\n      <li>Diazemuls (GB, IE, IT);</li>\n      <li>Diazepam (HK);</li>\n      <li>Diazepam Desitin (HU);</li>\n      <li>Diazepam-Eurogenerics (LU);</li>\n      <li>Diazepam-ratiopharm (LU);</li>\n      <li>Diazepan (AE, BF, BH, BJ, CI, CY, EG, ES, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Diazepeks (LV);</li>\n      <li>Dipezona (AR);</li>\n      <li>Dizam (ZW);</li>\n      <li>Dizep (BD);</li>\n      <li>Doval (ZA);</li>\n      <li>Dupin (TW);</li>\n      <li>DZP (MY);</li>\n      <li>Elcion CR (IN);</li>\n      <li>Euphorin (JP);</li>\n      <li>Evalin (BD);</li>\n      <li>Gewacalm (AT);</li>\n      <li>Horizon (JP);</li>\n      <li>Ifa Fonal (MX);</li>\n      <li>Kratium (BF, BJ, BM, BS, BZ, CI, ET, GH, GM, GN, GY, JM, KE, LR, MA, ML, MR, MU, MW, NE, NG, NL, PR, SC, SD, SL, SN, SR, TN, TR, TT, TZ, UG, ZM, ZW);</li>\n      <li>Lembrol (AR);</li>\n      <li>Melode (KR);</li>\n      <li>Nercon (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Nivalen (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Nixtensyn (PH);</li>\n      <li>Noan (BR, IT);</li>\n      <li>Normabel (HR);</li>\n      <li>Orinil (BD);</li>\n      <li>Ortopsique (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Paceum (CH);</li>\n      <li>Pacitran (PE);</li>\n      <li>Pamizep (PH);</li>\n      <li>Paranten (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Pax (ZA);</li>\n      <li>Paxum (IN);</li>\n      <li>Placidox 10 (IN);</li>\n      <li>Placidox 2 (IN);</li>\n      <li>Placidox 5 (IN);</li>\n      <li>Plidan (AR);</li>\n      <li>Propam (NZ);</li>\n      <li>Prozepam (ID);</li>\n      <li>Psychopax (AT, CH);</li>\n      <li>Radizepam (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Ranzepam (AU);</li>\n      <li>Relanium (LT, PL, RU);</li>\n      <li>Relium (UA);</li>\n      <li>Remedium (MT, TR);</li>\n      <li>Renborin (JP);</li>\n      <li>Sedium (PY);</li>\n      <li>Seduxen (BD, BM, BS, BZ, EE, GY, JM, NL, PR, SR, TT, VN);</li>\n      <li>Serenzin (JP);</li>\n      <li>Sincronex (UY);</li>\n      <li>Sipam (TH);</li>\n      <li>Solina (LK);</li>\n      <li>Stedon (MT);</li>\n      <li>Stesolid (AE, BH, CH, CY, DE, DK, EG, ES, FI, ID, IE, IL, IQ, IR, IS, JO, LK, LY, NO, OM, QA, SA, SE, SY, TW, YE);</li>\n      <li>Stesolid Rectal Tube (DE, HK);</li>\n      <li>Sunzepam (MX);</li>\n      <li>Sunzepan (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Sybazon (UA);</li>\n      <li>Talema (VE);</li>\n      <li>Tranquirit (IT);</li>\n      <li>Valaxona (DK);</li>\n      <li>Valdimex (ID);</li>\n      <li>Valiquid (DE);</li>\n      <li>Valisanbe (ID);</li>\n      <li>Valium (AE, AR, AT, AU, BB, BE, BF, BG, BH, BJ, BR, CH, CI, CR, CU, CY, DE, DK, DO, EC, EE, EG, ES, ET, FR, GH, GM, GN, GR, GT, HN, HR, IE, IN, IQ, IR, IT, JO, KE, KR, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NO, OM, PA, PE, PH, PK, PL, PT, PY, QA, SA, SC, SD, SK, SL, SN, SV, SY, TN, TR, TZ, UG, UY, VN, YE, ZM, ZW);</li>\n      <li>Valiuzam (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Valpam (AE, AU, BH, CY, EG, HK, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Valzepam (PH);</li>\n      <li>Vanconin (TW);</li>\n      <li>Vatran (IT);</li>\n      <li>Vexepam (PH);</li>\n      <li>Vodin (ID);</li>\n      <li>Zopam (TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diazepam-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics; American Academy of Pediatric Dentistry, Cot&eacute; CJ, et al, &quot;Guidelines for Monitoring and Management of Pediatric Patients During and After Sedation for Diagnostic and Therapeutic Procedures: An Update,&quot; <i>Pediatrics</i>, 2006, 118(6):2587-602.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diazepam-pediatric-drug-information/abstract-text/17142550/pubmed\" target=\"_blank\" id=\"17142550\">17142550</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diazepam-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bergman U, Rosa FW, Baum C, et al, &quot;Effects of Exposure to Benzodiazepine During Fetal Life,&quot; <i>Lancet</i>, 1992, 340(8821):694-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diazepam-pediatric-drug-information/abstract-text/1355799/pubmed\" target=\"_blank\" id=\"1355799\">1355799</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brophy GM, Bell R, Claassen J, et al. Guidelines for the evaluation and management of status epilepticus. <i>Neurocrit Care</i>. 2012;17(1):3-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diazepam-pediatric-drug-information/abstract-text/22528274 /pubmed\" target=\"_blank\" id=\"22528274 \">22528274 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a>http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diazepam-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cloyd JC, Lalonde RL, Beniak TE, Novack GD. A single-blind, crossover comparison of the pharmacokinetics and cognitive effects of a new diazepam rectal gel with intravenous diazepam. <i>Epilepsia</i>. 1998;39(5):520-526. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diazepam-pediatric-drug-information/abstract-text/9596205/pubmed\" target=\"_blank\" id=\"9596205\">9596205</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Delgado MR, Hirtz D, Aisen M, et al, &quot;Practice Parameter: Pharmacologic Treatment of Spasticity in Children and Adolescents With Cerebral Palsy (An Evidence-Based Review): Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society,&quot; <i>Neurology</i>, 2010, 74(4):336-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diazepam-pediatric-drug-information/abstract-text/20101040/pubmed\" target=\"_blank\" id=\"20101040\">20101040</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diazepam injection [prescribing information]. Lake Forest, IL: Hospira Inc; February 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dreifuss FE, Rosman NP, Cloyd JC, et al, &ldquo;A Comparison of Rectal Diazepam Gel and Placebo for Acute Repetitive Seizures,&rdquo; <i>N Engl J Med</i>, 1998, 338(26):1869-75. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diazepam-pediatric-drug-information/abstract-text/ 9637805 /pubmed\" target=\"_blank\" id=\" 9637805 \"> 9637805 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Engle HA, &quot;The Effect of Diazepam (Valium) in Children With Cerebral Palsy: A Double-Blind Study,&quot; <i>Dev Med Child Neurol</i>, 1966, 8(6):661-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diazepam-pediatric-drug-information/abstract-text/5339679/pubmed\" target=\"_blank\" id=\"5339679\">5339679</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Everitt IJ, Barnett P. Comparison of two benzodiazepines used for sedation of children undergoing suturing of a laceration in an emergency department.<i> Pediatr Emerg Care</i>. 2002;18(2):72-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diazepam-pediatric-drug-information/abstract-text/11973494 /pubmed\" target=\"_blank\" id=\"11973494 \">11973494 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fell D, Gough MB, Northan AA, Henderson CU. Diazepam premedication in children. Plasma levels and clinical effects. <i>Anaesthesia</i>. 1985;40(1):12-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diazepam-pediatric-drug-information/abstract-text/3970333 /pubmed\" target=\"_blank\" id=\"3970333 \">3970333 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Greenblatt DJ, Ehrenberg BL, Gunderman J, et al. Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. <i>Clin Pharmacol Ther</i>. 1989a;45(4):356-365.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diazepam-pediatric-drug-information/abstract-text/2702793 /pubmed\" target=\"_blank\" id=\"2702793 \">2702793 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Greenblatt DJ, Harmatz JS, Friedman H, Locniskar A, Shader RI. A large-sample study of diazepam pharmacokinetics. <i>Ther Drug Monit</i>. 1989b;11(6):652-657. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diazepam-pediatric-drug-information/abstract-text/2512694 /pubmed\" target=\"_blank\" id=\"2512694 \">2512694 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harden CL, Meador KJ, Pennell PB, et al, &quot;Practice Parameter Update: Management Issues for Women With Epilepsy-Focus on Pregnancy (an Evidence-Based Review): Teratogenesis and Perinatal Outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society,&quot; <i>Neurology</i>, 2009, 73(2):133-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diazepam-pediatric-drug-information/abstract-text/19398681/pubmed\" target=\"_blank\" id=\"19398681\">19398681</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hegenbarth MA and American Academy of Pediatrics Committee on Drugs, &quot;Preparing for Pediatric Emergencies: Drugs to Consider,&quot; <i>Pediatrics</i>, 2008, 121(2):433-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diazepam-pediatric-drug-information/abstract-text/18245435/pubmed\" target=\"_blank\" id=\"18245435\">18245435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hurst S, McMillan M. Innovative solutions in critical care units: extravasation guidelines. <i>Dimens Crit Care Nurs</i>. 2004;23(3):125-128.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diazepam-pediatric-drug-information/abstract-text/15192356/pubmed\" target=\"_blank\" id=\"15192356\">15192356</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Iqbal MM, Sobhan T, Ryals T, et al, &quot;Effects of Commonly Used Benzodiazepines on the Fetus, the Neonate, and the Nursing Infant,&quot; <i>Psychiatr Serv</i>, 2002, 53(1):39-49.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diazepam-pediatric-drug-information/abstract-text/11773648/pubmed\" target=\"_blank\" id=\"11773648\">11773648</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson' s Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Krauss B and Green SM, &quot;Procedural Sedation and Analgesia in Children,&quot; <i>Lancet</i>, 2006, 367(9512):766-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diazepam-pediatric-drug-information/abstract-text/16517277/pubmed\" target=\"_blank\" id=\"16517277\">16517277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lamson MJ, Sitki-Green D, Wannarka GL, Mesa M, Andrews P, Pellock J. Pharmacokinetics of diazepam administered intramuscularly by autoinjector versus rectal gel in healthy subjects: a phase I, randomized, open-label, single-dose, crossover, single-centre study. <i>Clin Drug Investig</i>. 2011;31(8):585-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diazepam-pediatric-drug-information/abstract-text/21721594 /pubmed\" target=\"_blank\" id=\"21721594 \">21721594 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marshall JD, Farrar HC, and Kearns GL, &ldquo;Diarrhea Associated With Enteral Benzodiazepine Solutions,&rdquo; <i>J Pediatr</i>, 1995, 126(4):657-9. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diazepam-pediatric-drug-information/abstract-text/7699551/pubmed\" target=\"_blank\" id=\"7699551\">7699551</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mathew A, Mathew MC, Thomas M, et al, &quot;The Efficacy of Diazepam in Enhancing Motor Function in Children With Spastic Cerebral Palsy,&quot; <i>J Trop Pediatr</i>, 2005, 51(2):109-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diazepam-pediatric-drug-information/abstract-text/15840761/pubmed\" target=\"_blank\" id=\"15840761\">15840761</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Milsap RL, Jusko WJ. Pharmacokinetics in the infant. <i>Environ Health Perspect</i>. 1994;102 Suppl 11:107-110.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diazepam-pediatric-drug-information/abstract-text/7737034/pubmed\" target=\"_blank\" id=\"7737034\">7737034</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morselli PL, Franco-Morselli R, Bossi L. Clinical pharmacokinetics in newborns and infants. Age-related differences and therapeutic implications. <i>Clin Pharmacokinet</i>. 1980;5(6):485-527.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morselli PL, Principi N, Tognoni G, et al. Diazepam elimination in premature and full term infants, and children. <i>J Perinat Med</i>. 1973;1(2):133-141.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diazepam-pediatric-drug-information/abstract-text/4806567 /pubmed\" target=\"_blank\" id=\"4806567 \">4806567 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosman NP, Colton T, Labazzo J, et al, &ldquo;A Controlled Trial of Diazepam Administered During Febrile Illnesses to Prevent Recurrence of Febrile Seizures,&rdquo; <i>N Engl J Med</i>, 1993, 329(2):79-84. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diazepam-pediatric-drug-information/abstract-text/8510706 /pubmed\" target=\"_blank\" id=\"8510706 \">8510706 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diazepam-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, &quot;Febrile Seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,&quot; <i>Pediatrics</i>, 2008, 121(6):1281-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diazepam-pediatric-drug-information/abstract-text/18519501/pubmed\" target=\"_blank\" id=\"18519501\">18519501</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tyagi P, Dixit U, Tyagi S, Jain A. Sedative effects of oral midazolam, intravenous midazolam and oral diazepam. <i>J Clin Pediatr Dent</i>. 2012;36(4):383-388.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diazepam-pediatric-drug-information/abstract-text/23019837 /pubmed\" target=\"_blank\" id=\"23019837 \">23019837 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vinkers CH, Olivier B. Mechanisms underlying tolerance after long-term benzodiazepine use: a future for subtype-selective GABA(A) receptor modulators? <i>Adv Pharmacol Sci</i>. 2012;2012:416864.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diazepam-pediatric-drug-information/abstract-text/22536226 /pubmed\" target=\"_blank\" id=\"22536226 \">22536226 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wikner BN, Stiller CO, Bergman U, et al, &quot;Use of Benzodiazepines and Benzodiazepine Receptor Agonists During Pregnancy: Neonatal Outcome and Congenital Malformations,&quot; <i>Pharmacoepidemiol Drug Saf</i>, 2007, 16(11):1203-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diazepam-pediatric-drug-information/abstract-text/17894421/pubmed\" target=\"_blank\" id=\"17894421\">17894421</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wlodarczyk BJ, Palacios AM, George TM, et al, &quot;Antiepileptic Drugs and Pregnancy Outcomes,&quot; <i>Am J Med Genet A</i>, 2012, 158A(8):2071-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diazepam-pediatric-drug-information/abstract-text/22711424/pubmed\" target=\"_blank\" id=\"22711424\">22711424</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization, WHO Technical Note. Current recommendations for the treatment of tetanus during humanitarian emergencies. January 2010. Available at: http://www.who.int/diseasecontrol_emergencies/who_hse_gar_dce_2010_en.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diazepam-pediatric-drug-information/abstract-text/17555487 /pubmed\" target=\"_blank\" id=\"17555487 \">17555487 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zeltzer LK, Altman A, Cohen D, et al, &ldquo;Report of the Subcommittee on the Management of Pain Associated With Procedures in Children With Cancer,&rdquo; <i>Pediatrics</i>, 1990, 86(5 Pt 2):826-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diazepam-pediatric-drug-information/abstract-text/2216645/pubmed\" target=\"_blank\" id=\"2216645\">2216645</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13223 Version 240.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50711533\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F49351801\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F159030\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F159031\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1052159\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442291\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1052150\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F159001\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F158984\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F159082\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F49627710\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1052165\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F159023\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1052164\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F159090\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F159087\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F159009\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F158988\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25855859\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F159074\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F158993\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F158996\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F159013\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1052158\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1052163\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F158987\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F159008\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F159012\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F159015\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13223|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=diazepam-drug-information\" class=\"drug drug_general\">Diazepam: Drug information</a></li><li><a href=\"topic.htm?path=diazepam-patient-drug-information\" class=\"drug drug_patient\">Diazepam: Patient drug information</a></li></ul></div></div>","javascript":null}